Andrew G Cheetham
Overview
Explore the profile of Andrew G Cheetham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1069
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheetham A, Plunkett S, Campbell P, Hilldrup J, Coffa B, Gilliland 3rd S, et al.
PLoS One
. 2022 Apr;
17(4):e0267049.
PMID: 35421170
There is significant regulatory and economic need to distinguish analytically between tobacco-derived nicotine (TDN) and synthetic nicotine (SyN) in commercial products. Currently, commercial e-liquid and oral pouch products are available...
2.
Su H, Wang F, Wang Y, Cheetham A, Cui H
J Am Chem Soc
. 2019 Oct;
141(43):17107-17111.
PMID: 31614088
Nanostructured supramolecular polymers (SPs) are filamentous assemblies possessing a high degree of internal order and have important uses in regenerative medicine, drug delivery, and soft matter electronics. Despite recent advances...
3.
Jablonski J, Maines J, Cheetham A, Gillman I
Regul Toxicol Pharmacol
. 2019 Sep;
108:104453.
PMID: 31473262
The recent 2016 deeming of cigars by the US Food and Drug Administration (FDA) has led to increased interest in cigar science, including ways to accurately measure the harmful and...
4.
Lin Y, Kang M, Chen W, Ou Y, Cheetham A, Wu P, et al.
Biomater Sci
. 2017 Dec;
6(1):216-224.
PMID: 29214247
Supramolecular filament hydrogels are an emerging class of biomaterials that hold great promise for regenerative medicine, tissue engineering, and drug delivery. However, fine-tuning of their bulk mechanical properties at the...
5.
Cheetham A, Chakroun R, Ma W, Cui H
Chem Soc Rev
. 2017 Oct;
46(21):6638-6663.
PMID: 29019492
Covalent modification of therapeutic compounds is a clinically proven strategy to devise prodrugs with enhanced treatment efficacies. This prodrug strategy relies on the modified drugs that possess advantageous pharmacokinetic properties...
6.
Chen Z, Xing L, Fan Q, Cheetham A, Lin R, Holt B, et al.
Theranostics
. 2017 Jun;
7(7):2003-2014.
PMID: 28656057
We report here on the covalent conversion of the anti-inflammatory agent ketoprofen into self-assembling prodrugs that enable the effective purification of ketoprofen enantiomers, the improved selectivity and potency of ketoprofen,...
7.
Cheetham A, Lin Y, Lin R, Cui H
Acta Pharmacol Sin
. 2017 Mar;
38(6):874-884.
PMID: 28260797
The conjugation of small molecular hydrophobic anticancer drugs onto a short peptide with overall hydrophilicity to create self-assembling drug amphiphiles offers a new prodrug strategy, producing well-defined, discrete nanostructures with...
8.
Ma W, Su H, Cheetham A, Zhang W, Wang Y, Kan Q, et al.
J Control Release
. 2017 Jan;
263:102-111.
PMID: 28082170
The direct use of anticancer drugs to create their own nanostructures is an emerging concept in the field of drug delivery to obtain nanomedicines of high drug loading and high...
9.
Wang Y, Cheetham A, Angacian G, Su H, Xie L, Cui H
Adv Drug Deliv Rev
. 2016 Jul;
110-111:112-126.
PMID: 27370248
Peptide-drug conjugates (PDCs) represent an important class of therapeutic agents that combine one or more drug molecules with a short peptide through a biodegradable linker. This prodrug strategy uniquely and...
10.
Su H, Zhang P, Cheetham A, Koo J, Lin R, Masood A, et al.
Theranostics
. 2016 May;
6(7):1065-74.
PMID: 27217839
Chemical modification of small molecule hydrophobic drugs is a clinically proven strategy to devise prodrugs with enhanced treatment efficacy. While this prodrug strategy improves the parent drug's water solubility and...